New Leukemia Drug Testing Tool Shows Early Promise
A new microfluidic assay could help clinicians better predict which drug combinations are most effective for pediatric leukemia.
Updated on Oct. 28, 2026 in Cancer
Live Poll
Should hospitals adopt personalized lab-on-a-chip technology to speed up cancer treatment decisions?
Researchers in Atlanta have developed a new microfluidic assay called GradientScreen to test how childhood leukemia cells respond to specific drug combinations. This pilot study, which analyzed samples from 17 patients, may eventually help clinicians predict treatment efficacy for pediatric acute lymphoblastic leukemia.
Why it matters
Current leukemia treatments often lack personalized tools to predict how an individual patient will respond to specific drug combinations. This platform aims to address that gap, potentially improving how doctors approach care for the 15% of pediatric patients who experience relapse.
This preliminary study evaluated 17 leukemia cell and bone marrow samples using the GradientScreen assay. Researchers found the results correlated with patient residual disease levels, though the tool is still being validated for broader clinical use.
The players
Emory University
A research university based in Atlanta that houses the Emory Lab for Innovative Assay Development.
Georgia Tech
A research institution in Atlanta that collaborated on the development of the microfluidic technology.
Children's Healthcare of Atlanta
A pediatric hospital system home to the Aflac Cancer and Blood Disorders Center.
The details
The GradientScreen assay functions by exposing leukemia cells to various ratios of three-drug combinations within a microfluidic environment. This allows researchers to measure cancer cell survival rates across multiple drug concentrations simultaneously in a single experiment. By observing how these cells respond to different mixtures, the system seeks to identify which therapeutic approaches might be most effective for individual patient profiles.
Timeline
October 27, 2026: Emory Health Sciences released the findings of the study.
Health Landscape
This research reflects a growing shift toward microfluidics to enable personalized cancer care. It builds upon efforts at the Emory Lab for Innovative Assay Development to create systems that can better predict treatment success than standard trial-and-error approaches.
While this tool is currently in the research phase, it highlights the importance of discussing precision medicine options with your hematologist or oncologist. Families managing pediatric leukemia may consider asking their care team about whether local clinical trials involving new diagnostic assays are available.
The takeaway
The GradientScreen assay represents an early-stage attempt to improve leukemia treatment by identifying the most effective drug combinations in a lab setting. Patients and caregivers should continue to work closely with their oncology team to stay updated on the latest personalized treatment options.
Further reading
For more information on the latest research in this field, visit our Cancer section.
Source note: This article includes information reported by News-Medical.
Live Poll
Should hospitals adopt personalized lab-on-a-chip technology to speed up cancer treatment decisions?
